Press Releases

• An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy
• SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg
• No dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)
• Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all... (continue reading...)

BEIJING, May 30, 2024 /PRNewswire/ -- This is a report from China.org.cn about the Shaolin Temple:

Jason Castleton visited the Shaolin Temple, which is known as the birthplace of Chinese kung fu. The temple, located in Dengfeng, Henan Province, was founded in 495 and is also considered the ancestral monastery of Chan Buddhism. It is not only a popular tourist attraction, but also a World Heritage Site.

Jason meets his friend Jia, who has been studying kung fu at... (continue reading...)

• Study shows that FPM data can be reliably and quickly generated even through minimally invasive small-needle biopsies, which may expand the accessibility of FPM to provide personalized treatment validation and recommendations.

• NIMHD-funded study explores the relationship between biomarkers and racial/ethnic differences in response to cancer therapies to address existing health disparities.

• New research builds on a body of clinical evidence published in the... (continue reading...)

OSAKA, Japan--(BUSINESS WIRE)-- The city of Tondabayashi in Osaka is excited to announce a new inbound tour by "SABIWabisabi," aimed at revitalizing the local community. This exclusive tour combines traditional Japanese cultural experiences with gourmet meals using premium ingredients, all set in a historic Japanese house. Reservations open on June 1, 2024.

This press release features multimedia. View the full release here: ... (continue reading...)

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment

Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue

CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc.... (continue reading...)